GlassScriptPhysician profile
Jyothi Mandava
NPI 1891809539
$6,694.43
in general payments reported to CMS, 2019-2025
32 companies · $728 in 2025
The $728 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,393 · 2020: $527 · 2021: $1,058 · 2022: $910 · 2023: $1,203 · 2024: $875 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,793.54 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $1,018.61 | 2019-2024 | Adzenys Xr-Odt |
| Abbvie INC. | $735.12 | 2021-2025 | |
| Alkermes, INC. | $515.09 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $475.04 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $392.41 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $388.59 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $358.55 | 2022-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $350.14 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $344.13 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $338.89 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $334.92 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.48 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $198.98 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $185.73 | 2023-2025 | Auvelity |
| Allergan, INC. | $164.81 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $89.91 | 2019-2022 | |
| Eisai INC. | $78.82 | 2020-2021 | |
| Tris Pharma INC | $67.22 | 2023-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $54.71 | 2021-2024 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $51.65 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $38.38 | 2022 | |
| Jazz Pharmaceuticals INC. | $35.60 | 2019-2021 | |
| Sage Therapeutics, LLC | $32.95 | 2024-2025 | Zurzuvae |
| Aytu Biopharma, INC. | $31.16 | 2021 | |
| Livanova USA, INC. | $29.53 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Adlon Therapeutics L.P. | $25.27 | 2020 | |
| Avanir Pharmaceuticals, INC. | $19.75 | 2019 | |
| Noven Therapeutics, LLC | $15.89 | 2023 | Xelstrym |
| Currax Pharmaceuticals LLC | $15.10 | 2019 | |
| Neuronetics, INC. | $14.17 | 2019 | |
| Mdd US Operations, LLC | $13.72 | 2019 | |
| Indivior INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyothi Mandava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.